NLRP3 and obesity disorder: These findings align with a recently published study demonstrating that direct inhibition of NLRP3 with MCC950, targeting the NATCH domain, mitigates airway hyperresponsiveness (AHR) and inflammatory cell recruitment in an obesity-induced mode [36].